Time to treatment failure. The composite outcome of platelet count < 50 × 109/L, significant bleeding, or rescue treatment was measured among patients receiving rituximab (solid line) or placebo (dashed line) plus standard treatment. The x-axis is time in observation period once standard treatment was discontinued.